Pathnostics of Irvine unveiled a molecular diagnostic test that can detect COVID-19, influenza A/B and respiratory syncytial virus with a nasal swab sample and a single test panel.
The company announced the expanded offering at the end of October as part of its goal to help the medical community “prepare for the prospect of a ‘perfect storm’ of escalating COVID-19 pandemic cases at the same time as a seasonal influenza epidemic.”
About 20% of COVID-19 patients are estimated to experience co-infection with influenza or respiratory syncytial virus, according to a recent study published in the Journal of the American Medical Association.
Pathnostics’ main product is the Guidance UTI test that simultaneously diagnoses and guides antibiotic treatment for complex, recurring urinary tract infections.
Guidance UTI test results were associated with a 13.7% reduction in hospitalization compared to a group that used standard urine culture testing, according to a study published in the JOJ Urology and Nephrology Journal in March.
The company’s Guidance UTI, COVID-19 and respiratory pathogens tests recently became available to various government-funded home health programs.
